NEW YORK, June 11, 2020 — Milu Labs, which seeks to produce the most sophisticated diagnostics in women’s health across Asia, is pleased to announce that it has been selected as a finalist in the China Healthcare Innovation Platform (CHIP) competition.
CHIP is administered by the China Europe International Business School (CEIBS) and honors companies that are developing groundbreaking technologies in the life sciences field. It has chosen Milu Labs for its innovative exosome-based platform.
“We at Milu are thrilled to be finalists at CHIP,” said Dr. Wilson Zhang, CEO of Milu Labs. “We are excited to be recognized for the work we have been doing in furthering the state-of-the-art of women’s health diagnostics.”
Winners will be announced on July 11.
About Milu Labs
Milu Labs is a global diagnostics company that builds, researches, and markets cutting edge technologies to screen and detect major health conditions. The company focuses exclusively on the best technologies, from those in early development to those that are already commercialized. Milu Labs is collaborating with global academic institutions and top American healthcare companies to develop the most exciting diagnostic technologies.
For more information, visit us at www.milulabs.com
About CEIBS
The China Europe International Business School is the leading business school in China and consistently ranks among the best in the world. The Financial Times rates its full-time MBA program as the fifth best program globally.
English 
Chinese